Adjustment of telomere length by telomerase is considered as a biological marker which determine the proliferation of cancer cells.
3D-Printed Wearable Personalized Orthodontic Retainers for Sustained Release of Clonidine Hydrochloride
Orthodontic retainers are wearable customizable medical devices for dental protection or alignment.
Pharmacodynamic Effects of Sulbactam/Meropenem/Polymyxin-B Combination Against Extremely Drug Resistant Acinetobacter baumannii Using Checkerboard Information
Aim: The aims of the study are to evaluate the activity of sulbactam, meropenem, and polymyxin B alone and in combination against six isolates of extremely drug resistant...
Complementary HPLC, in silico toxicity, and molecular docking studies for investigation of the potential influences of gastric acidity and nitrite content on paracetamol safety
This study was initiated for investigating the possible gastro-transformations that may affect the integrity and safety of the most commonly administered analgesic and antipyretic, paracetamol (PCM).
Simulations Plus Enters into New Research Collaboration Agreement with the FDA
Center for Veterinary Medicine to apply GastroPlus® to assess product bioequivalence in canines
Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part I. Mechanistic modelling of drug product dissolution to derive a P-PSD for PBPK model input
Drug product dissolution for four batches of acalabrutinib 100 mg capsules were analyzed with in vitro dissolution in various pH conditions and in media containing synthetic surfactant micelles or biorelevant micelles.
Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juices
Acalabrutinib (Calquence®) 100 mg (bid) has received accelerated approval by FDA for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Concepts of Artificial Intelligence for Computer-Assisted Drug Discovery
Artificial intelligence (AI), and, in particular, deep learning as a subcategory of AI, provides opportunities for the discovery and development of innovative drugs.
Simulations Plus Reports Third Quarter FY2019 Financial Results
Record quarter as revenues grow 16%, 9MoFY19 revenues up 13%
Board of Directors announces quarterly dividend of $0.06 per share
PKPlus™ 2.5 Release Webinar
Learn about the latest developments in PKPlus™
1-Methyl-1,2,3,4-tetrahydroisoquinoline – The toxicological research on an exo/endogenous amine with antidepressant-like activity – In vivo, in vitro and in silico studies
1-Methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ) demonstrates significant neuroprotective activity.
Simulations Plus Upgrades PKPlus™
Enhancements include improved data handling and command line functionality
A repository of protein abundance data of drug metabolizing enzymes and transporters for applications in physiologically based pharmacokinetic (PBPK) modelling and simulation
Population factors such as age, gender, ethnicity, genotype and disease state can cause inter-individual variability in pharmacokinetic (PK) profile of drugs.
Integration of In Silico Pharmacokinetic Modeling Approaches Into In Vitro Dissolution Profiles to Predict Bioavailability of a Poorly Soluble Compound
The objective of present study is to develop pharmacokinetic (PK) prediction methods using in silico PK model for oral immediate release drug products (i.e. solution, suspension, and amorphous solid dispersion).
Reactivation potency of two novel oximes (K456 and K733) against paraoxon-inhibited acetyl and butyrylcholinesterase: In silico and in vitro models
Organophosphates (OPs) irreversibly inhibit acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzymes.
Simulations Plus Sets Date for 3rd Quarter 2019 Earnings Release and Conference Call
Conference Call to be on Wednesday, July 10, 2019, at 4:15 PM ET
Verubecestat Pharmacokinetic and Exposure-Response Results From APECS, a Phase 3 Trial in Prodromal Alzheimer’s Disease
The BACE inhibitor verubecestat (MK-8931) demonstrated cognitive and functional decline relative to placebo in a 2-year Phase 3 trial of individuals with prodromal AD (APECS; NCT01953601), along with...
In silico Tools at Early Stage of Pharmaceutical Development: Data Needs and Software Capabilities
In early drug development, the selection of a formulation platform and decisions on formulation strategies have to be made within a short timeframe and often with minimal use of the active pharmaceutical ingredient (API).